Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

D. Edelstein, M. Brownlee

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

We studied the effect of aminoguanidine, an inhibitor of advanced glycation product formation, on albuminuria in chronically diabetic spontaneously hypertensive rats. At the time of killing, there was no statistically significant difference in blood glucose concentration between the treated and untreated diabetic animals (18.2±0.69 mmol/l), nor was there any difference among the non-diabetic, diabetic untreated, and diabetic treated rats with respect to blood pressure (169±6.9 mm Hg). However, non-diabetic hypertensive animals had a mean quantitative 24-h urinary albumin excretion of 28±2 mg albumin/24-h, while untreated diabetic hypertensive animals averaged nearly four times that amount (106 ±3 mg albumin/24 h). Without affecting blood pressure, aminoguanidine treatment of diabetic hypertensive animals decreased the diabetic-associated elevation in urinary albumin excretion by 75% (48±2 mg/24 h). These data suggest than inhibition of advanced glycation product formation ameliorates the glomerular dysfunction caused by chronic hyperglycaemia.

Original languageEnglish (US)
Pages (from-to)96-97
Number of pages2
JournalDiabetologia
Volume35
Issue number1
DOIs
StatePublished - Jan 1992

Fingerprint

Albuminuria
Albumins
Blood Pressure
Inbred SHR Rats
Hyperglycemia
Blood Glucose
pimagedine

Keywords

  • aminoguanidine
  • diabetes
  • glycation
  • hypertension
  • Nephropathy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. / Edelstein, D.; Brownlee, M.

In: Diabetologia, Vol. 35, No. 1, 01.1992, p. 96-97.

Research output: Contribution to journalArticle

Edelstein, D. ; Brownlee, M. / Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. In: Diabetologia. 1992 ; Vol. 35, No. 1. pp. 96-97.
@article{058f430766694f0d8c64b585911504f8,
title = "Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats",
abstract = "We studied the effect of aminoguanidine, an inhibitor of advanced glycation product formation, on albuminuria in chronically diabetic spontaneously hypertensive rats. At the time of killing, there was no statistically significant difference in blood glucose concentration between the treated and untreated diabetic animals (18.2±0.69 mmol/l), nor was there any difference among the non-diabetic, diabetic untreated, and diabetic treated rats with respect to blood pressure (169±6.9 mm Hg). However, non-diabetic hypertensive animals had a mean quantitative 24-h urinary albumin excretion of 28±2 mg albumin/24-h, while untreated diabetic hypertensive animals averaged nearly four times that amount (106 ±3 mg albumin/24 h). Without affecting blood pressure, aminoguanidine treatment of diabetic hypertensive animals decreased the diabetic-associated elevation in urinary albumin excretion by 75{\%} (48±2 mg/24 h). These data suggest than inhibition of advanced glycation product formation ameliorates the glomerular dysfunction caused by chronic hyperglycaemia.",
keywords = "aminoguanidine, diabetes, glycation, hypertension, Nephropathy",
author = "D. Edelstein and M. Brownlee",
year = "1992",
month = "1",
doi = "10.1007/BF00400859",
language = "English (US)",
volume = "35",
pages = "96--97",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

AU - Edelstein, D.

AU - Brownlee, M.

PY - 1992/1

Y1 - 1992/1

N2 - We studied the effect of aminoguanidine, an inhibitor of advanced glycation product formation, on albuminuria in chronically diabetic spontaneously hypertensive rats. At the time of killing, there was no statistically significant difference in blood glucose concentration between the treated and untreated diabetic animals (18.2±0.69 mmol/l), nor was there any difference among the non-diabetic, diabetic untreated, and diabetic treated rats with respect to blood pressure (169±6.9 mm Hg). However, non-diabetic hypertensive animals had a mean quantitative 24-h urinary albumin excretion of 28±2 mg albumin/24-h, while untreated diabetic hypertensive animals averaged nearly four times that amount (106 ±3 mg albumin/24 h). Without affecting blood pressure, aminoguanidine treatment of diabetic hypertensive animals decreased the diabetic-associated elevation in urinary albumin excretion by 75% (48±2 mg/24 h). These data suggest than inhibition of advanced glycation product formation ameliorates the glomerular dysfunction caused by chronic hyperglycaemia.

AB - We studied the effect of aminoguanidine, an inhibitor of advanced glycation product formation, on albuminuria in chronically diabetic spontaneously hypertensive rats. At the time of killing, there was no statistically significant difference in blood glucose concentration between the treated and untreated diabetic animals (18.2±0.69 mmol/l), nor was there any difference among the non-diabetic, diabetic untreated, and diabetic treated rats with respect to blood pressure (169±6.9 mm Hg). However, non-diabetic hypertensive animals had a mean quantitative 24-h urinary albumin excretion of 28±2 mg albumin/24-h, while untreated diabetic hypertensive animals averaged nearly four times that amount (106 ±3 mg albumin/24 h). Without affecting blood pressure, aminoguanidine treatment of diabetic hypertensive animals decreased the diabetic-associated elevation in urinary albumin excretion by 75% (48±2 mg/24 h). These data suggest than inhibition of advanced glycation product formation ameliorates the glomerular dysfunction caused by chronic hyperglycaemia.

KW - aminoguanidine

KW - diabetes

KW - glycation

KW - hypertension

KW - Nephropathy

UR - http://www.scopus.com/inward/record.url?scp=0026584035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026584035&partnerID=8YFLogxK

U2 - 10.1007/BF00400859

DO - 10.1007/BF00400859

M3 - Article

C2 - 1541387

AN - SCOPUS:0026584035

VL - 35

SP - 96

EP - 97

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 1

ER -